Lille (France), June 22nd, 2021 - ALZPROTECT, a biopharmaceutical company engaged in the development of drugs for the treatment of Alzheimer's disease, announced today that Dr. John Tchelingerian has joined the Board of Directors of Alzprotect. Alzprotect is financed by the Xerys Funds.


Dr John Tchelingerian is a serial entrepreneur in life sciences. As a veteran of the industry, he co-founded and/or lead several biotech companies as CEO or Chairman & CEO. He raised a total of over €200 million of funding during his career and achieved together with his teams to bring five drug candidates from research to the clinics (up to phase IIb/III) and realized several international pharmaceuticals partnering and M&A deals. He is currently the Managing Partner and co-founder of two specialized strategic advisory firms, The Connecting Architects and Silver Ocean Ventures and Chairman of Pan-Cancer T’s Supervisory Board. He is a PhD graduate in Neurosciences from Pierre et Marie Curie University in Paris.

Dr. John Tchelingerian commented:  « I am delighted joining the board of Alzprotect as a Director to contribute to the company’s growth and its success. The company has made remarkable progress since the first time I met Philippe and his team a few years ago. I am convinced that Alzprotect will be a game changer in the field of PSP with its drug-candidate AZP-2006, currently in phase 2a clinical trials in Europe. »

Dr Philippe Verwaerde, President of Alzprotect, declared: "John's profile and experience are valuable assets to strengthen our board of directors on the eve of a strategic inflection point and a rise in development of Ezeprogind / AZP2006 "

Lille (France), May 11th - Alzprotect, biopharmaceutical company developing therapeutic solutions for neurodegenerative diseases, and the Adolphe de Rothschild Foundation Hospital announced today the signing of a collaboration agreement. This first materializes with the opening in Paris, within the Rothschild Foundation Hospital of the 3rd clinical center, as part of the phase 2a trial aimed at evaluating the safety of the main drug candidate of the company, EZEPROGIND (AZP2006) for the treatment of progressive supranuclear palsy (PSP). PSP is an orphan disease for which Alzprotect has obtained "orphan drug" status from the Food and Drug Administration (FDA) and the European Medicines Agency. Alzprotect is financed by the Xerys funds.

With EZEPROGIND, Alzprotect mainly targets two neurodegenerative diseases: Progressive Supranuclear Palsy (PSP) for which there is no treatment to date and Alzheimer's disease, recognized as a major public health issue, currently without any reliable early diagnosis or treatment that can modify the course of the disease.

Dr Pierre Le Sourd, member of the Supervisory Board of Xerys Gestion and member of the Board of Directors of Alzprotect, declares “It is our duty at Xerys to invest in companies whose mission is to identify solutions for diseases that are public health priorities. We are proud of this scientific partnership with the Adolphe de Rothschild Foundation Hospital. This is a very strong signal. I would like to thank Mr. Julien Gottsmann as well as all the teams who make it possible to accelerate this project to fight neurodegenerative diseases. "

Monsieur Julien Gottsmann, CEO of the Rothschild Foundation Hospital emphasizes: "The signing of this agreement with the biotechnology company Alzprotect will allow us to jointly conduct a clinical trial to evaluate a treatment against Progressive Supranuclear Palsy. This partnership signed within the framework of Rothschild Medical Development brings hope for treatments to patients suffering from PSP. "

 Dr Michael Alexandre Obadia, neurologist at the Rothschild Foundation Hospital adds: "Supra-nuclear paralysis is a severe pathology with a poor prognosis; the development of new therapies is a major issue in this field. I look forward to participating in this ambitious project on behalf of the Hospital and the collaboration that is beginning with the Alzprotect teams. "

Dr Philippe Verwaerde, President of Alzprotect, said: “We are very excited to start this collaboration and to benefit from the internationally recognized expertise of the Rothschild Foundation Hospital and its teams in the field of neurology. The hospital is also monitoring a large number of PSP patients, which will allow us to complete our phase 2a study, and hopefully continue to develop our scientific collaboration. "

Lille (France), April 8th, 2021 – Alzprotect, a biopharmaceutical company developing therapeutic solutions for neurodegenerative diseases announces today today hat it has established its US based subsidiary, Alzprotect US Inc. in Boston, Massachusetts, in line with its international development strategy.

This new subsidiary of Alzprotect is situated in Boston. The world’s ten largest biopharma companies have a presence in Massachusetts, making it an ideal location for scientific and technological innovation and ideally suited for Alzprotect’ first US foothold.

The creation of this affiliate is the first milestone in a process that will lead to the initiation of Alzprotect’ clinical trials for the treatment of PSP and Alzheimer’s disease in the US.

Dr Philippe Verwaerde, CEO of Alzprotect, commented: “The creation of a subsidiary in the US is an important step forward in our strategy as set out in our future development. This further strengthens the international reach of our innovative pipeline for the treatment of neurodegeneration. We are very excited to become part of the biotechnology cluster in Cambridge and believe this prime location will prove to be extremely beneficial to the Company as we move our clinical development forward in this important market.”

Lille (France), March 7th, 2021 – Alzprotect, a biopharmaceutical company developing therapeutic solutions for neurodegenerative diseases is pleased to announce the company will present virtually at the 14th Annual European Life Sciences CEO Forum that will take place from  the 10th  to the 12th of March 2021, aspart of the Digital Sachs Spring Life Sciences Week.

Philippe Verwaerde, Chief Executive Officer of Alzprotect will provide an overview of the development program of the company’s drug Ezeprogind® and will be available for questions and one-on-one meetings with attendees registered for the conference.

Dr Verwaerde will also participate in a “Progress in Alzheimer’s Dementia and Diagnostic” panel on March 11th at 5 PM.

 “There is currently no available treatment to slow down or stop diseases related to neurodegeneration which affect tens of millions of people worldwide. Participating in this event allows us to share our unique innovation and progress involving the regulation of complex intracellular processes including inflammatory pathways and neuronal survival. Along with our experts, partners, and investors, we are proud of our recent progress and look forward to the next steps” Dr. Verwaerde said.

The 14th Annual ELSF is will include the BioCapital & Investment Day and the Bio-Pharma Partnering & Therapeutics Day on 10th and 11th of March. These two days will feature more than 14 hours of high-level speeches, panel discussions and spotlight showcases by more than 400 leading industry corporates.

Lille (France), November 23rd, 2020 – Alzprotect, a biopharmaceutical company developing therapeutic solutions for neurodegenerative diseases announces today that the United States Patent and Trademark Office (USPTO) has recently granted patent number US 10,772,884 concerning the therapeutic uses of its first-in-class clinical stage drug Ezeprogind (AZP2006) in the treatment of tauopathies. This patent completes the Ezeprogind related patents granted in the USA for composition of matter (US 9,562,018) and therapeutic uses in the treatment of Alzheimer’s and Parkinson’s diseases (US 10,537,569).

This strengthens Alzprotect portfolio of patents covering Ezeprogind that were already granted in Europe (EP 2 938 597 - validated in 26 member states of the European Patent Convention), and in 11 other countries including Japan (JP 6384923) and China (CN 105008333).

All these patents will be in force until at least 27th December 2033, subject to patent term adjustment or extension, and similar applications are currently under examination in Canada and Brazil.

Alzprotect co-owns or has an exclusive worldwide license from the French National Institute of Health and Medical research (Inserm) and the University of Lille (France) on a total of 58 patents related to Ezeprogind in 39 countries.

Alzprotect continues to expand the Ezeprogind intellectual property with the filing of two new European priority patent applications that will be extended to several other countries outside Europe directed to novel therapeutic uses for specific neurodegenerative diseases as well as new forms of the molecule intended for solid formulations of the drug.

Philippe Verwaerde, Chairman & Chief Executive Officer of Alzprotect, declared: “This new granted patent will reinforce our strong intellectual property portfolio which is a major asset for our company. I am also happy to extend it with two new applications in both therapeutic and formulation fields.

Cyrille Brantis, Intellectual Property Manager of Alzprotect, declared: “The grant of Ezeprogind composition of matter and therapeutic use patents in several major countries worldwide provides a significant protection of Ezeprogind’s intellectual property and is a key milestone for Alzprotect. The new patent applications are the outcome of years of high-quality research engaged by Alzprotect and highlight the company’s commitment to the development Ezeprogind.”  

Alzprotect is financed by the XERYS fund (Paris).

Interview Biotech Finances  25/06/2020